The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Hepatitis C virus drug resistance–associated substitutions: State of the art summary
Open accessAbstract
Hepatitis C virus (HCV) drug development has resulted in treatment regimens composed of interferon‐free, all‐oral combinations of direct‐acting antivirals. While the new regimens are potent and highly efficacious, the full clinical impact of HCV drug resistance, its implications for retreatment, and the potential role of baseline resistance testing remain critical research and clinical questions. In this report, we discuss the viral proteins targeted by HCV direct‐acting antivirals and summarize clinically relevant resistance data for compounds that have been approved or are currently in phase 3 clinical trials. Conclusion : This report provides a comprehensive, systematic review of all resistance information available from sponsors’ trials as a tool to inform the HCV drug development field. (H epatology 2015;62:1623–1632)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy
Neumann, A. U., Lam, N. P., Dahari, H., Gretch, D. R., Wiley, T. E., Layden, T. J., & Perelson, A. S. (1998) · Science · doi:10.1126/science.282.5386.103 · Cited by 2,113
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Afdhal, N., Zeuzem, S., Kwo, P., Chojkier, M., Gitlin, N., Puoti, M., Romero-Gomez, M., Zarski, J.-P., Agarwal, K., Buggisch, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402454 · Cited by 1,705
Self-citationMansky, L. M., & Temin, H. M. (1995) · Journal of Virology · doi:10.1128/jvi.69.8.5087-5094.1995 · Cited by 1,154
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J.-H., O’Boyle II, D. R., et al. (2010) · Nature · doi:10.1038/nature08960 · Cited by 939
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
Feld, J. J., Kowdley, K. V., Coakley, E., Sigal, S., Nelson, D. R., Crawford, D., Weiland, O., Aguilar, H., Xiong, J., Pilot-Matias, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315722 · Cited by 903
Self-citationABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
Poordad, F., Hezode, C., Trinh, R., Kowdley, K. V., Zeuzem, S., Agarwal, K., Shiffman, M. L., Wedemeyer, H., Berg, T., Yoshida, E. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402869 · Cited by 874
Lawitz, E., Sulkowski, M. S., Ghalib, R., Rodriguez-Torres, M., Younossi, Z. M., Corregidor, A., DeJesus, E., Pearlman, B., Rabinovitz, M., Gitlin, N., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61036-9 · Cited by 818
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Zeuzem, S., Dusheiko, G. M., Salupere, R., Mangia, A., Flisiak, R., Hyland, R. H., Illeperuma, A., Svarovskaia, E., Brainard, D. M., Symonds, W. T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316145 · Cited by 795
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Gane, E. J., Stedman, C. A., Hyland, R. H., Ding, X., Svarovskaia, E., Symonds, W. T., Hindes, R. G., & Berrey, M. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208953 · Cited by 764
Nelson, D. R., Cooper, J. N., Lalezari, J. P., Lawitz, E., Pockros, P. J., Gitlin, N., Freilich, B. F., Younes, Z. H., Harlan, W., Ghalib, R., et al. (2015) · Hepatology · doi:10.1002/hep.27726 · Cited by 689
Self-citationNucleotide sequence and mutation rate of the H strain of hepatitis C virus.
Ogata, N., Alter, H. J., Miller, R. H., & Purcell, R. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.8.3392 · Cited by 606
Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
Zeuzem, S., Jacobson, I. M., Baykal, T., Marinho, R. T., Poordad, F., Bourlière, M., Sulkowski, M. S., Wedemeyer, H., Tam, E., Desmond, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401561 · Cited by 517
Self-citationResistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
Sarrazin, C., & Zeuzem, S. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.11.055 · Cited by 504
Jacobson, I. M., Dore, G. J., Foster, G. R., Fried, M. W., Radu, M., Rafalsky, V. V., Moroz, L., Craxi, A., Peeters, M., Lenz, O., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60494-3 · Cited by 437
Self-citationManns, M., Marcellin, P., Poordad, F., de Araujo, E. S. A., Buti, M., Horsmans, Y., Janczewska, E., Villamil, F., Scott, J., Peeters, M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60538-9 · Cited by 376
Self-citationManns, M., Pol, S., Jacobson, I. M., Marcellin, P., Gordon, S. C., Peng, C.-Y., Chang, T.-T., Everson, G. T., Heo, J., Gerken, G., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61059-x · Cited by 342
Self-citationExploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
Poordad, F., Lawitz, E., Kowdley, K. V., Cohen, D. E., Podsadecki, T., Siggelkow, S., Heckaman, M., Larsen, L., Menon, R., Koev, G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208809 · Cited by 285
Self-citationHCV direct‐acting antiviral agents: the best interferon‐free combinations
Schinazi, R., Halfon, P., Marcellin, P., & Asselah, T. (2014) · Liver International · doi:10.1111/liv.12423 · Cited by 230
Curing Chronic Hepatitis C — The Arc of a Medical Triumph
Chung, R. T., & Baumert, T. F. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1400986 · Cited by 227
The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors
Romano, K. P., Ali, A., Aydin, C., Soumana, D., Özen, A., Deveau, L. M., Silver, C., Cao, H., Newton, A., Petropoulos, C. J., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002832 · Cited by 219
Polymerase structures and function: variations on a theme?
Joyce, C. M., & Steitz, T. A. (1995) · Journal of Bacteriology · doi:10.1128/jb.177.22.6321-6329.1995 · Cited by 194
Berger, C., Romero‐Brey, I., Radujković, D., Terreux, R., Zayas, M., Paul, D., Harak, C., Hoppe, S., Gao, M., Pénin, F., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.019 · Cited by 158
MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease
Liverton, N. J., Carroll, S. S., DiMuzio, J. M., Fandozzi, C. M., Graham, D. J., Hazuda, D. J., Holloway, M. K., Ludmerer, S. W., McCauley, J. A., McIntyre, C. J., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00677-09 · Cited by 141
Lenz, O., Verbinnen, T., Fevery, B., Tambuyzer, L., Vijgen, L., Peeters, M., Buelens, A., Ceulemans, H., Beumont, M. G., Picchio, G., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.032 · Cited by 132
Self-citationResistance Analysis of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir
McPhee, F., Friborg, J., Levine, S., Chen, C., Falk, P. J., Yu, F., Hernandez, D., Lee, M. S., Chaniewski, S., Sheaffer, A. K., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00308-12 · Cited by 110
Self-citationAntiviral Resistance and the Future Landscape of Hepatitis C Virus Infection Therapy
Wyles, D. L. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis761 · Cited by 108
Morine, Y., Shimada, M., & Utsunomiya, T. (2013) · Hepatology Research · doi:10.1111/hepr.12107 · Cited by 61
Dore, G. J., Lawitz, E., Hézode, C., Shafran, S. D., Ramji, A. S., Tatum, H. A., Taliani, G., Tran, A., Brunetto, M. R., Zaltron, S., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.10.007 · Cited by 58
Self-citationKwong, A. D., Nájera, I., Bechtel, J. T., Bowden, S., Fitzgibbon, J. E., Harrington, P. R., Kempf, D. J., Kieffer, T. L., Koletzki, D., Kukolj, G., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.01.029 · Cited by 37
Self-citationAccelerating Drug Development Through Collaboration: The Hepatitis C Drug Development Advisory Group
Hutchison, C. A., Kwong, A. D., Ray, S. C., Struble, K. A., Swan, T., & Miller, V. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.113 · Cited by 16
Self-citation
Cited by
Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens
Pawlotsky, J.-M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.04.003 · Cited by 519
Hepatitis C virus NS3/4a protease inhibitors
McCauley, J. A., & Rudd, M. T. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.07.015 · Cited by 120
Metadata
- Authors
- Lontok, E., Harrington, P., Howe, A., Kieffer, T., Lennerstrand, J., Lenz, O., McPhee, F., Mo, H., Parkin, N., Pilot‐Matias, T., & Miller, V.
- Venue
- Hepatology
- Published
- 2015-07-30
- Volume
- 62
- Issue
- 5
- Pages
- 1623-1632
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W1826210767
- Cited by
- 275
- References
- 30
- FWCI
- 28.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.